Successful lung transplantation from a hepatitis C RNA –positive donor to a hepatitis C treatment–experienced recipient with cystic fibrosis

The advent of direct-acting antivirals (DAAs) in 2014 has transformed the landscape of hepatitis C virus (HCV) treatment, allowing patients to achieve cure after 8 to 12  weeks of safe and well-tolerated therapy.1 Because of the already limited organ donor pool and the availability of high numbers of HCV-viremic donors resulting from the opioid epidemic, this development has led to immense interest in transplanting organs from HCV-viremic donors into nonviremic rec ipients.2 In 2017, the first pilot of 10 noninfected patients who received kidney transplants from HCV-viremic donors demonstrated excellent allograft and patient outcomes, with cure of HCV infection using DAAs after transplant.
Source: The Journal of Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: Case Report Source Type: research